Value of Time and Money
Applied Clinical Trials
Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.
Industry Standard Research has recently released its 3rd annual "CRO Quality Benchmarking Report." The report not only profiles the delivery quality of leading CROs, but also provides a wealth of information that relates to larger industry trends, including the value of recruitment speed.
After three consecutive years of collecting data, a critical mass to reflect upon has been collected. The basic statistics class axiom: "It takes three data points to make a trend," has been met.
Source: ISR Reports: Survey participants were asked to indicate their preference for one benefit over the other. n=160 (2009); 150 (2010); 169 (2011)
After examining the data, it is clear and undeniable: sponsors are expressing an unmet need for faster recruitment. It's not difficult to make sense of this. Project manager job appraisals and compensation are tied to trial speed. In addition, the rule-of-thumb is that for each day's delay in getting a drug to market, the manufacturer loses a million dollars in revenue. Perhaps to some readers this qualifies as a "duh" take-away, but the magnitude of the disparity remains interesting—price is important too.
Patient recruitment continues to be a source of consternation in the industry, and service providers are constantly measured against this metric. The ones that do it well will establish loyalty among their customers and the ones that do it poorly will struggle.
—Industry Standard Research, www.ISRreports.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
